Edwards Lifesciences Corp $ 231.25 -2.66 (-1.14%)
Volume:
844,745
Avg Vol (1m):
1,292,548
Market Cap $:
48.36 Bil
Enterprise Value $:
47.52 Bil
P/E (TTM):
46.81
P/B:
11.63
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 2.24 | ||
| Equity-to-Asset | 0.64 | ||
| Debt-to-Equity | 0.16 | ||
| Debt-to-EBITDA | 0.53 | ||
| Piotroski F-Score | 6 | ||
| Altman Z-Score | 14.86 | ||
| Beneish M-Score | -2.33 | ||
| WACC vs ROIC | |||
Profitability Rank | 9/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 28.49 | ||
| Net Margin % | 24.08 | ||
| ROE % | 29 | ||
| ROA % | 18.16 | ||
| ROC (Joel Greenblatt) % | 73.4 | ||
| 3-Year Revenue Growth Rate | 14.6 | ||
| 3-Year EBITDA Growth Rate | 16.5 | ||
| 3-Year EPS without NRI Growth Rate | 23.6 |
Valuation Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 46.81 | ||
| Forward PE Ratio | 36.9 | ||
| PE Ratio without NRI | 46.81 | ||
| Price-to-Owner-Earnings | 64.15 | ||
| PB Ratio | 11.63 | ||
| PS Ratio | 11.29 | ||
| Price-to-Free-Cash-Flow | 54.48 | ||
| Price-to-Operating-Cash-Flow | 41.61 | ||
| EV-to-EBIT | 40.03 | ||
| EV-to-EBITDA | 37.23 | ||
| EV-to-Revenue | 10.93 | ||
| PEG Ratio | 12 | ||
| Shiller PE Ratio | 88.3 | ||
| Current Ratio | 3.31 | ||
| Quick Ratio | 2.6 | ||
| Days Inventory | 204.04 | ||
| Days Sales Outstanding | 45.63 | ||
| Days Payable | 59.09 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 18.24 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 3.61 | ||
| Price-to-Intrinsic-Value-DCF (Earnings Based) | 1.89 | ||
| Price-to-Median-PS-Value | 1.75 | ||
| Price-to-Peter-Lynch-Fair-Value | 8.24 | ||
| Price-to-Graham-Number | 6.17 | ||
| Earnings Yield (Greenblatt) % | 2.5 | ||
| Forward Rate of Return (Yacktman) % | 6.98 |